Smile Doctors and Dental Monitoring Expand and Accelerate Partnership to Provide Remote Monitoring to All Patients During the State of Emergency
20.3.2020 17:24:00 EET | Business Wire | Press release
Smile Doctors, the largest US based Orthodontic DSO (Dental Support Organization), with over 220 locations in 17 States, has signed a deal with Dental Monitoring to use its suite of AI powered remote monitoring solutions to provide industry leading patient access and convenience. Importantly, the original partnership agreed after several months of pilots and testing, has been expanded and accelerated to include all patients eligible with immediate effect this week, due to the Coronavirus national situation. All eligible Smile Doctors patients will therefore be able to start or continue their treatment remotely with Dental Monitoring.
Dental Monitoring will provide access to and training for all Smile Doctors specialist orthodontist clinics nationwide to all DM products, including SmileMate, Vision and Dental Monitoring.
- SmileMate enables virtual consultations with prospective new patients at home, offering an almost instant oral health assessment through photos taken with the patient’s own smartphone.
- Vision uses AI to produce within seconds an instant simulation of the patient’s face with different orthodontic appliances and also generates state-of-the-art simulation of post-treatment smiles, using the actual details of the patient’s teeth and gums, helping the patient choose their treatment with more confidence.
- Dental Monitoring uses AI to allow the Doctor to remotely monitor the progress of the patient’s treatment through photos taken by the patient using the DM app on their own smartphone, with a DM ScanBox. The Dental Monitoring solution allows real time communication between the Doctor’s team and the patient.
Commenting on the deal, CEO of Smile Doctors, J. Hedrick explained: “I am delighted to have achieved this partnership with Dental Monitoring, which I am certain will be to the extreme benefit to all of our patients. Dental Monitoring’s AI technology and patient user experience is second to none, and has brought dentistry up to speed with patients’ expectations in a digital world. The initial reception by both clinical team and patients in our pilots has been extremely positive, and we believe we have a unique differentiator in our offering to our Smile Doctors patients.”
CEO and Co-Founder of Dental Monitoring, Philippe Salah, added: “Smile Doctors for us is the ideal partner as we accelerate our growth in the US. We have established a true partnership where we will help Smile Doctors to fully utilize the full suite of DM products. We enable their orthodontists to address the needs of new patients, allow more of them to say yes to treatment, and then monitor their treatment progress efficiently, using our DM proprietary AI engine.”
On the acceleration of the partnership due to the current Coronavirus crisis, J. Hedrick said: “We decided to fast track our implementation of DM full heartedly throughout our entire network to make sure we could continue to serve our patients with the best clinical care. Dental Monitoring has been a unique and essential partner for us, and we are excited to be rolling out this service at such speed to respond to the crisis. I am grateful to Philippe and the DM team for really working side by side with us on this 24/7 in the interests of our patients.”
About Dental Monitoring (www.dental-monitoring.com)
Founded in 2015 by Philippe Salah, Dental Monitoring is the first AI-based company to target dental professionals’ needs. The DM software suite is designed to address the needs of dental professionals all along the patient journey: before treatment to increase the patient’s engagement, during treatment to improve the quality of care provided by the doctor, and after treatment to ensure the stability of the treatment outcome. The company currently operates in Europe, the United States and Asia-Pacific. It employs a team of about 250 employees across its 5 offices located in Paris, Austin, London, Hong Kong, and Sydney. For more information, please visit www.dental-monitoring.com.
About Smile Doctors, LLC ( www.smiledoctors.com )
Smile Doctors, LLC is the largest orthodontic dental support organization with more than 200 affiliated practices in 17 states. Based in Georgetown, TX and founded by Dr. Scott Law, Scotte Hudsmith, Dr. Dana Fender, and Dr. Greg Goggans, Smile Doctors focuses exclusively on developing and growing affiliated orthodontic practices. Orthodontists can focus on patient care while receiving the support of experienced professionals who are committed to the growth and success of their practices. Support provided by Smile Doctors includes services related to operations, accounting, marketing, and revenue cycle. For more information, please visit www.smiledoctors.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200320005353/en/
Contact information
Contact Dental Monitoring: Charlotte Garzino c.garzino@dental-monitoring.com
Contact SmileDoctor: Jessica Lynch, VP Operations - Jessica.Lynch@smiledoctors.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN ® APN6.8.2026 07:30:00 EEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom